• DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

Forgotten and with few treatment options, Chagas debilitates and kills

Rio de Janeiro, Brazil — 9 Jul 2009
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

100 years since Chagas disease was discovered, DNDi launches an international campaign “Wake Up. Time to Treat Chagas Disease!” with a call for better medicines and treatment of patients
[Português]

One hundred years after the discovery of Chagas disease, 100 million people remain at risk and the disease continues to debilitate and kill the poorest of the poor. Drugs for Neglected Diseases initiative (DNDi) today, alongside Médecins Sans Frontières (MSF), called on governments, scientific community, private sector and civil society to increase their commitment and support for research and development for better health tools (diagnostics and treatments) and improved access.

The global campaign “Wake Up.Time to Treat Chagas Disease!” was launched during a three-day international scientific conference on the 100th anniversary of the discovery of Chagas disease, and also comes at the time of a publication of a series of articles in PLoS Neglected Tropical Diseases on the unfinished public health agenda of Chagas disease.

“We hope this campaign will bring Chagas disease out of the shadows and helps patients with Chagas disease to gain access to better treatment options, ” said Michel Lotrowska, DNDi’s Regional Director for Latin America. “Little public or political capital currently exists for Chagas disease as the disease most affects the most vulnerable populations in some of the poorest regions in Latin American countries. Only a global effort can put Chagas disease on the top of national and international agenda.”

Few of the millions of patients needing treatment for Chagas disease are ever diagnosed with the disease and receive treatment. When they do, there are only two medications available – benznidazole and nifurtimox, both of which have a number of disadvantages: treatment is long (30 to 60 days), with side effects and high rates of patient non-compliance. There is limited efficacy in the advanced stages of the disease, and no pediatric strength or formulation is currently available.

“This international meeting shows there is renewed interest by scientists and practitioners to find new and better treatments to fight Chagas, but we also need sustainable funding and political commitment to make it,” commented Dr. Carlos Morel, Director of the Center for Technological Development in Health (CDTS) of FIOCRUZ. “We must unite the growing capabilities of developing countries to combine innovation in health with the scientific advances being made in research and development at leading institutes worldwide.”

As reported in PLoS articles, Chagas disease remains at the top of the list of most neglected diseases today despite improved control and regional research efforts.1-3 Despite being responsible for one of the highest estimated disease burdens due to infectious diseases in Latin America, Chagas disease received only 0.25% (approximately US$10 million) out of 2.5 billion dollars invested in neglected diseases in 2007.4

The Chagas Campaign launched by DNDi (www.treatchagas.org), aims to raise awareness of the burden of Chagas disease and calls upon those in power to foster innovation for this silent disease by supporting innovative partnerships in R&D and facilitating new and sustainable financing mechanisms.

“Chagas patients have been forgotten because they are poor and live in remote and rural areas, but we see that the science exists to develop better treatments,” said Bernard Pecoul, Executive Director of DNDi. “The first step to making progress at an international level is through sustainable funding and strong public support in both endemic and non-endemic countries. The draft resolution on neglected diseases, which is being considered by PAHO/WHO this year, is one example where we are moving forward and must follow through with concrete action.”

Note for Editors

About Chagas disease

Chagas is primarily transmitted by large, blood-sucking reduviid insects widely known as “the kissing bug”, Chagas is endemic in 21 countries across Latin America, With an average of 14,000 deaths per year, Chagas kills more people in the region each year than any other parasite-born disease, including malaria. These are mostly poor people who live in rural areas or migrate to the outskirts of larger urban centers and therefore don’t represent an attractive enough consumer market for private industry.

Without an adequate diagnosis and treatment, one in every four Chagas patients develops a fatal symptom of the disease, usually swelling of the heart muscle. Often, patients will require a pace-maker and in some cases even need to undergo a heart transplant. Many patients, however, die suddenly, some without even realizing that they had been infected.

Children born to mothers who know that they are infected by the Trypanosoma cruzi parasite can benefit the most from treatment and the cure rate is high.  Yet, there are no pediatric treatments available that have been adapted to their needs. Children are treated with adult medication, broken up into as many as 12 pieces, depending on the child’s body weight. As the medication is non-soluble, mothers have to crush the medication to dissolve it in liquid. This not only puts the continuity of the treatment at risk, but also its safety and efficacy, as it is difficult to ensure a correct dosage.

This problem is beginning to be resolved with the production of pediatric benznidazole that will be available in 2010 thanks to a partnership between DNDi and LAFEPE (the pharmaceutical lab of the state of Pernambuco in Brazil), the only producer of benznidazole in the world.

About DNDi

The Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit product development partnership founded in 2003 by five publicly-funded research organisations –  Brazil’s Oswaldo Cruz Foundation, Indian Council of Medical Research, Kenya Medical Research Institute, Malaysian Ministry of Health, and the Institut Pasteur; an international research organisation WHO’s Tropical Diseases Research programme; and an international humanitarian organisation Médecins Sans Frontières. DNDi has developed the largest ever R&D portfolio for kinetoplastid diseases and has, with its partners, already made available three new treatments for neglected diseases. For further information, please visit www.dndi.org.

This month, in a DNDi has published a policy paper in PLOS NTD outlining the urgent need for new treatments for Chagas disease, examining barriers to development and evaluation of new drugs, and reporting on progress in bringing new treatments to patients.  In the short term, DNDi is working on better use of existing treatments through therapeutic switching, new formulations (including the first pediatric formulation of benznidazole), and combination therapies based on the success of such treatments in HIV/AIDS, malaria and tuberculosis. DNDi’s long-term objectives are to deliver an effective, non-toxic, inexpensive treatment proven effective in both acute and early chronic phases, and to improve research & treatment capacity for Chagas disease.

References
1. Franco-Paredes C, Bottazzi ME, Hotez PJ. The unfinished public health agenda of chagas disease in the era of globalization. PLoS Negl Trop Dis. 2009;3(7):e470.
2. Ribeiro CH, Lopez NC, Ramirez GA, et al. Trypanosoma cruzi calreticulin: A possible role in Chagas’ disease autoimmunity. Mol Immunol. Mar 2009;46(6):1092-1099.
3. Yun O, Lima MA, Ellman T, et al. Feasibility, drug safety, and effectiveness of etiological treatment programs for chagas disease in honduras, guatemala, and bolivia: 10-year experience of medecins sans frontieres. PLoS Negl Trop Dis. 2009;3(7):e488.
4. Moran M, Guzman J, Ropars AL, et al. Neglected Disease Research and Development: How Much Are We Really Spending? PLoS Med. Feb 3 2009;6(2):e30.

Contacts
For further information or to arrange interviews with Michel Lotrowska or Carlos Morel, please contact:

Flávio Guilherme Pontes – DNDi Rio de Janeiro, Brazil, (21) 8123-4133; (21) 8298-6294; press@dndi.org.br

Samantha Bolton – DNDi Geneva, Switzerland, (41) 79 239 2366, (41) 22 906 9250; sbolton@dndi.org

Michelle French – DNDi New York, USA, (1) 646 616 8681; (1) 646 552 4600; mfrench@dndi.org.

Please visit the Chagas Campaign website: www.treatchagas.org

Policy advocacy Chagas disease

Read, watch, share

Loading...
Young man sitting in hospital setting
News
25 Jan 2023

It’s time medical innovation reached the 1.7 billion people affected by neglected tropical diseases: World NTD Day 2023

Film Poster Voices of Leishmaniasis: Shushi from India
Videos
25 Jan 2023

Voices of leishmaniasis: Shishu from India

Child receiving treatment
News
20 Jan 2023

DNDi’s 20th year of bringing the best science for the most neglected

Child affected by dengue and her mother at their home in Bangkok, Thailand.
Stories
16 Dec 2022

2022: Six advances in neglected disease research to remember

Statements
2 Dec 2022

DNDi‘s comments on the conceptual zero draft for the consideration of the Intergovernmental Negotiating Body at INB3

Healthcare workers discussing in hospital setting
Press releases
1 Dec 2022

DNDi partners in a new NIHR-funded Global Health Research Group on HIV-associated Fungal Infections (IMPRINT)

Healthcare workers looking into microscopes
Press releases
30 Nov 2022

Acoziborole: Investigational single-dose oral treatment raises hope for elimination of sleeping sickness in Africa

Journalists talking with healthcare workers
News
23 Nov 2022

DNDi media workshops – bringing together reporters and researchers to cover neglected disease research

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo